Research progress of targeting NOD-like receptor family Pyrin domain containing 3 inflammasome for the treatment of experimental MAFLD-associated liver fibrosis
10.3969/j.issn.1006-6187.2025.01.013
- VernacularTitle:NOD样受体家族Pyrin域蛋白3炎性小体对代谢相关脂肪性肝病肝纤维化机制的研究进展
- Author:
Dandan HAO
1
;
Lei ZHANG
;
Chunying BAI
Author Information
1. 024000 赤峰学院内蒙古人类遗传病研究重点实验室
- Publication Type:Journal Article
- Keywords:
Metabolic dysfunction-associated fatty liver disease;
Liver fibrosis;
Inflammasome
- From:
Chinese Journal of Diabetes
2025;33(1):73-76
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic dysfunction-associated fatty liver disease(MAFLD)is becoming an leading causes of hepatic fibrosis worldwide,resulting in MAFLD-related liver fibrosis.Emerging evidences have indicated that the activation of the NOD-like receptor family Pyrin domain containing 3(NLRP3)inflammasome is a critical contributor to the development of MAFLD-related liver fibrosis.This article reviews the mechanism by which NLRP3 inflammasome activation promotes the development of MAFLD-related liver fibrosis,and focuses on the pharmacological mechanism of drugs targeting NLRP3 inflammasome to treat MAFLD-related liver fibrosis.
